Oxaliplatin is contraindicated in patients who have/are:

- Platinum hypersensitivity anaphylaxis

- Posterior reversible encephalopathy syndrome

- Grade 3 or 4 peripheral sensory neuropathy

- Severe renal impairment

- Chronic lung disease

- Rhabdomyolysis

- Sepsis

- Pregnant or intending to get pregnant

- Breastfeeding

Use in the first trimester should be avoided due to high teratogenicity and embryoÂ or fetal death. Females of reproductive potential should have a pregnancy test prior to initiating therapy and must use appropriate contraception during treatment and for nine months following discontinuation of oxaliplatin. Male patients should continue contraception for six months following treatment cessation.